Related Experiment Video
Updated: Aug 12, 2026
08:56
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
Published on: February 10, 2015
[Inflammatory mediator in patients with obstructive jaundice and its effect on renal function]
1Department of Surgery, First Affiliated Hospital, WCUMS, Chengdu 610041, China.
Hua Xi Yi Ke Da Xue Xue Bao = Journal of West China University of Medical Sciences = Huaxi Yike Daxue Xuebao
|May 8, 2003
Summary
Inflammatory transmitters like endothelin (ET) and cytokines significantly increase in obstructive jaundice (OJ) patients post-surgery, correlating with kidney function markers. These findings highlight the link between inflammation and renal impairment in OJ.
Area of Science:
- Biochemistry
- Nephrology
- Immunology
Context:
- Obstructive jaundice (OJ) can lead to significant renal dysfunction.
- Inflammatory mediators are implicated in the pathophysiology of OJ-associated kidney injury.
Purpose:
- To investigate the impact of inflammatory transmitters on renal function in patients with obstructive jaundice.
- To assess the relationship between plasma inflammatory markers and urinary renal function markers in OJ.
Summary:
- Plasma levels of endothelin (ET), lipopolysaccharide (LPS), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-8 (IL-8) were significantly elevated in OJ patients compared to controls.
- Urinary retinol-binding protein (RBP), transferrin (TFR), and albumin (ALB) also showed significant increases in OJ patients.
- The temporal changes in plasma inflammatory markers mirrored those observed in urinary renal function markers.
Impact:
- These findings suggest a strong interaction between inflammatory transmitters and renal function impairment in the context of obstructive jaundice.
- Understanding this interaction may lead to novel therapeutic strategies for preventing or treating kidney damage in OJ patients.
Related Concept Videos
01:26Diseases of the Liver and Gallbladder
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
01:17Factors Affecting Renal Clearance: Renal Impairment
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
01:11Renal Failure: Dose Adjustments
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:25Jaundice
Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...